Skip to main content
Caplight Logo









Cantoni Therapeutics

Cantoni Therapeutics

Private
OssHealthcare & Life Scienceshttps://cantonitx.nl/

Last Round

Seed

Sep 16, 2025

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Cantoni Therapeutics is a biotechnology company developing small molecule inhibitors of nicotinamide N-methyltransferase (NNMT) for the treatment of obesity and its comorbidities.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting

AI Layer

Non-AI

Keywords

NNMT inhibitorssmall molecule inhibitorsobesity treatmentbisubstrate inhibitorsnon-incretin obesity treatmentweight loss drugsenergy expenditurecardiometabolic diseasepreclinical biotechdrug discoverynicotinamide N-methyltransferaseIND-enablinguniversity spin-out

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Cantoni Therapeutics Comparables

Compare Cantoni Therapeutics with similar companies based on industry and business-model similarity.

Cantoni Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Eolo Pharma
83%
Ridgeline Therapeutics
78%
Deep Apple Therapeutics
77%

Cantoni Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedSep 16, 2025
Pre SeedDec 1, 2022

Cantoni Therapeutics Investors

Notable investors and investment history

Cantoni Therapeutics investors
InvestorRounds
Brabantse Ontwikkelings MaatschappijSeed
Libertatis Ergo HoldingPre Seed, Seed
Brabant Startup FondsSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Sep 16, 2025

    Led by Libertatis Ergo Holding with participation from Brabant Startup Fonds and Brabantse Ontwikkelings Maatschappij.

  • Sep 19, 2024

    Grew 75% QoQ, from 4 to 7 employees.

Cantoni Therapeutics Filings

Explore SEC and related filing metadata, where available.

Cantoni Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Cantoni Therapeutics's valuation, stock price, and market status.

Is Cantoni Therapeutics a public or private company?

Cantoni Therapeutics is a private company.

What is the current stock price of Cantoni Therapeutics?

Cantoni Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is Cantoni Therapeutics worth (valuation)?

Valuation information for Cantoni Therapeutics is not publicly available.

Can I buy Cantoni Therapeutics stock?

Cantoni Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Cantoni Therapeutics's last funding round?

Cantoni Therapeutics's most recent funding round was Seed on September 16, 2025.

Who are the main investors in Cantoni Therapeutics?

Key investors in Cantoni Therapeutics include Libertatis Ergo Holding.

Will Cantoni Therapeutics IPO soon?

No public IPO plans have been announced for Cantoni Therapeutics.

How can I track Cantoni Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Cantoni Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersOss
Employee Range7
Year Founded2022
Last FundingSep 16, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?